Can I Take Zinc With Egrifta (Tesamorelin)?

Why This Combination Comes Up

Tesamorelin (brand name Egrifta SV) is the only FDA-approved growth hormone-releasing hormone (GHRH) analog indicated for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Zinc, meanwhile, is one of the most commonly used supplements among people living with HIV because of its role in immune regulation and its documented depletion in the setting of chronic viral infection.

The Clinical Overlap

Patients prescribed tesamorelin are often managing multiple aspects of metabolic and immune health simultaneously. A 2010 randomized controlled trial (N=816) demonstrated that tesamorelin 2 mg daily reduced trunk fat by 15.2% over 26 weeks compared to a 5.2% increase with placebo [1]. Many of those same patients may already be taking zinc based on evidence from Baum et al. (2010, N=231), a placebo-controlled trial showing that zinc supplementation at 12 mg/day for 18 months slowed immunological failure and reduced diarrhea incidence in HIV-positive adults on antiretroviral therapy [2].

Why Patients Ask

The concern typically arises because zinc influences the growth hormone (GH) axis. Zinc-deficient individuals show blunted GH responses to provocative testing, and repletion restores normal pulsatile GH secretion [3]. Patients logically wonder whether adding zinc could amplify or interfere with the pharmacologic GH release triggered by tesamorelin.

Pharmacokinetic Analysis: No Overlap in Absorption or Metabolism

Tesamorelin and zinc operate through entirely separate pharmacokinetic pathways. There is no mechanism by which one compound would alter the blood levels or clearance rate of the other.

Tesamorelin Pharmacokinetics

Tesamorelin is administered as a 2 mg subcutaneous injection into the abdomen. It reaches peak plasma concentration (Tmax) in approximately 0.15 hours, with a half-life of 26 minutes and an absolute bioavailability of roughly 4% [4]. The peptide is degraded by tissue and circulating proteases. It does not undergo hepatic cytochrome P450 metabolism, is not a substrate for P-glycoprotein efflux, and is not protein-bound in a way that would be subject to displacement interactions.

Zinc Pharmacokinetics

Elemental zinc is absorbed primarily in the duodenum and proximal jejunum via the ZIP4 transporter and divalent metal transporter 1 (DMT1). Absorption efficiency ranges from 16% to 50% depending on dose and dietary phytate content [5]. Once absorbed, zinc binds to albumin and alpha-2-macroglobulin in plasma. It is distributed intracellularly and stored in metallothionein. Excretion is primarily fecal, with minor urinary and integumentary losses.

The Bottom Line on PK

Because tesamorelin bypasses the gastrointestinal tract entirely and is catabolized by proteases (not CYP enzymes, not renal transporters), there is no pharmacokinetic node where zinc could alter tesamorelin levels or vice versa. This is a clean separation.

Pharmacodynamic Considerations: Zinc and the GH-IGF-1 Axis

While the pharmacokinetic picture is straightforward, the pharmacodynamic relationship is more nuanced. Zinc participates in growth hormone biology at multiple levels.

Zinc's Role in GH Secretion

Zinc is a cofactor for the enzyme that converts thyroxine (T4) to the active thyroid hormone triiodothyronine (T3), and T3 is a permissive factor for normal GH gene transcription in somatotrophs. In zinc-deficient states, GH secretion is impaired. A study by Nishi et al. (1989) found that zinc supplementation in short-statured children with zinc deficiency increased both serum zinc and GH responses to provocation testing [3].

For patients on tesamorelin, this means adequate zinc status may support (rather than interfere with) the drug's intended mechanism. Tesamorelin stimulates endogenous GH release from the pituitary; a zinc-replete state helps ensure the somatotrophs can respond optimally.

IGF-1 Signaling and Zinc

Zinc also influences downstream IGF-1 activity. The IGF-1 receptor is a tyrosine kinase, and zinc modulates phosphatase activity that regulates this receptor's signaling cascade. IGF-1 is the primary biomarker used to monitor tesamorelin efficacy. In the key Phase 3 trial, tesamorelin increased IGF-1 levels by a mean of 81 ng/mL from baseline [1]. There is no clinical evidence that zinc supplementation at physiologic doses (15 to 40 mg/day) causes clinically meaningful additive IGF-1 elevation beyond what tesamorelin produces.

Clinical Significance

The pharmacodynamic interaction is theoretical and directionally supportive, not antagonistic. Zinc repletion may modestly enhance the GH axis environment in which tesamorelin operates. This does not constitute a dangerous interaction. It does, however, reinforce the importance of monitoring IGF-1 levels as recommended in the Egrifta SV prescribing information [4].

The Real Risk: Zinc-Induced Copper Deficiency

The most clinically relevant concern when adding zinc to any long-term regimen is not a drug interaction. It is zinc's well-documented ability to deplete copper stores.

Mechanism of Copper Depletion

Zinc induces metallothionein synthesis in enterocytes. Metallothionein has a higher affinity for copper than for zinc. When enterocytes are loaded with metallothionein from high zinc intake, dietary copper is sequestered intracellularly and lost when the enterocyte is sloughed into the intestinal lumen every 3 to 5 days. This is not a minor academic observation. The FDA approved zinc acetate (Galzin) specifically for Wilson disease based on this copper-depleting mechanism [6].

Dose Thresholds

The NIH Office of Dietary Supplements sets the Tolerable Upper Intake Level (UL) for zinc at 40 mg/day of elemental zinc for adults [5]. Copper depletion has been documented at doses as low as 50 mg/day when taken for more than 6 weeks. Symptoms of copper deficiency include neutropenia, microcytic anemia that does not respond to iron, and peripheral neuropathy.

Why This Matters for Tesamorelin Patients

People living with HIV already face higher rates of peripheral neuropathy from antiretroviral-associated mitochondrial toxicity and from HIV itself. Adding iatrogenic copper deficiency on top of this existing vulnerability creates a compounding neuropathy risk. A case series by Nations et al. (2008) documented copper deficiency myeloneuropathy in patients taking zinc supplements in the 80 to 150 mg/day range [7].

Practical Guardrails

Keep elemental zinc at or below 40 mg/day. If using zinc doses above 25 mg/day for more than 8 weeks, add 1 to 2 mg/day of supplemental copper (typically as copper gluconate or copper bisglycinate) taken at a separate time from zinc. Monitor serum copper and ceruloplasmin at baseline and every 6 months.

Dose Separation: Is It Necessary?

Strict dose separation between zinc and tesamorelin is not pharmacologically required. Tesamorelin is injected subcutaneously, so oral zinc cannot interfere with its absorption. The concept of dose separation applies to oral drugs that compete for the same GI transporter or are chelated by divalent cations (for example, tetracyclines, fluoroquinolones, or levothyroxine with zinc).

When Separation Still Helps

If a patient takes other oral medications alongside zinc, a 2-hour window between zinc and those medications remains good clinical practice. Zinc can reduce absorption of penicillamine, certain cephalosporins, and quinolone antibiotics by forming insoluble chelates [8]. Spacing is about protecting the other medications in the regimen, not about protecting tesamorelin.

Injection Timing

Tesamorelin is typically injected once daily. There is no pharmacologic reason to time the injection relative to zinc supplementation. Patients can inject tesamorelin at any time of day and take zinc with a meal (which improves zinc tolerability and reduces nausea) without concern for interaction.

Monitoring Protocol When Combining Zinc and Tesamorelin

A structured monitoring approach ensures both compounds are working as intended and that copper stores remain intact.

Baseline Labs (Before Starting Zinc)

• Serum zinc (fasting, morning draw; zinc has diurnal variation)
• Serum copper and ceruloplasmin
• Complete blood count with differential (to detect neutropenia if copper is already low)
• IGF-1 (should already be monitored per Egrifta SV labeling)
• Fasting glucose and HbA1c (tesamorelin can impair glucose tolerance; zinc modestly improves insulin sensitivity in some populations)

Ongoing Monitoring (Every 6 Months)

• Serum zinc (target: 70 to 120 mcg/dL)
• Serum copper (target: 70 to 155 mcg/dL) and ceruloplasmin (target: 20 to 35 mg/dL)
• IGF-1 (the Endocrine Society recommends keeping IGF-1 within age-adjusted reference ranges during GH-axis therapies) [9]
• CBC with differential if copper trends downward

When to Reassess

Discontinue supplemental zinc or reduce the dose if serum copper drops below 70 mcg/dL, ceruloplasmin drops below 18 mg/dL, or unexplained neutropenia develops. The 2011 Endocrine Society clinical practice guidelines on GH use in adults note that IGF-1 should be maintained within the upper half of the normal range but not above it [9]. If IGF-1 exceeds the age-adjusted upper limit, the tesamorelin dose and any supplements that could theoretically support GH secretion should be reviewed.

Zinc Dosing Recommendations for Tesamorelin Patients

Not every patient on tesamorelin needs zinc supplementation. The decision should be based on documented deficiency or clear clinical indication.

Who Should Supplement

• Patients with measured serum zinc below 70 mcg/dL
• Patients with HIV who have chronic diarrhea (a major cause of zinc loss), as documented in the Baum et al. Trial [2]
• Patients with inadequate dietary zinc intake (less than 8 mg/day for women, less than 11 mg/day for men)

Recommended Forms and Doses

Zinc picolinate, zinc bisglycinate, and zinc citrate have superior bioavailability compared to zinc oxide. A dose of 15 to 30 mg/day elemental zinc covers most deficiency states without approaching the copper-depletion threshold. The Baum et al. Trial used 12 mg/day and achieved meaningful immunologic benefit [2].

What to Avoid

Avoid zinc doses above 40 mg/day without physician oversight and concurrent copper supplementation. Avoid combining zinc with iron supplements at the same time of day, as they compete for DMT1 transport [8]. Do not take zinc simultaneously with fluoroquinolone antibiotics (common in HIV care for opportunistic infection prophylaxis), as zinc chelation can reduce antibiotic efficacy by up to 50% [8].

What to Do If You Are Already Taking Both

Patients who are already combining tesamorelin and zinc do not need to stop either one. The steps below apply to anyone currently on this combination.

Step 1: Confirm Your Zinc Dose

Check the label for elemental zinc content. Many supplements list the total weight of the zinc compound (e.g., zinc gluconate 100 mg), but the elemental zinc fraction is lower (approximately 14.3 mg for 100 mg zinc gluconate). If elemental zinc exceeds 40 mg/day, reduce to 25 to 30 mg/day.

Step 2: Check Copper Status

Request serum copper and ceruloplasmin at your next lab draw. If values are normal, continue current zinc dose with monitoring every 6 months.

Step 3: Review Full Supplement Stack

Zinc interacts with iron, calcium, and certain antibiotics. Bring a complete supplement list to your prescriber so dose spacing can be optimized across the entire regimen.

Step 4: Track IGF-1

Ensure IGF-1 is being monitored per the Egrifta SV label. If IGF-1 rises above the age-adjusted reference range, discuss with your prescriber whether zinc or tesamorelin dose adjustments are appropriate.

Testosterone, Zinc, and Tesamorelin: A Common Three-Way Question

Many tesamorelin patients are men with HIV who also receive testosterone replacement therapy (TRT). Zinc enters this conversation because of its role in testosterone metabolism.

Zinc and Testosterone

A frequently cited study by Prasad et al. (1996) demonstrated that zinc restriction in young men reduced serum testosterone by approximately 75% over 20 weeks, and zinc supplementation in marginally deficient older men increased testosterone from 8.3 nmol/L to 16.0 nmol/L over 6 months [10]. Zinc is a cofactor for 5-alpha reductase, which converts testosterone to dihydrotestosterone (DHT), and also inhibits aromatase, the enzyme that converts testosterone to estradiol.

Clinical Relevance

For patients on tesamorelin and TRT simultaneously, zinc repletion may modestly support testosterone efficacy. This is not a dangerous potentiation. It is a physiologic optimization. Serum testosterone, free testosterone, estradiol, and SHBG should be part of routine TRT monitoring regardless of zinc status.

As the Endocrine Society's 2018 guidelines on testosterone therapy state: "Clinicians should monitor hematocrit, PSA, testosterone levels, and liver function at regular intervals during testosterone treatment" [11]. Adding zinc to this equation does not change the monitoring cadence, though it does add copper and ceruloplasmin to the lab panel.